Martin Hutchings

32PUBLICATIONS
206CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Oncology and carcinogenesis not elsewhere classifiedApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (32)

|Aug 17, 2026
Glofitamab in combination with immunochemotherapy in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Phase 1b dose-escalation study.

|Jul 16, 2026
Englumafusp alfa plus glofitamab in B cell non-Hodgkin lymphoma: a phase 1 trial.

|Jul 14, 2026
Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial.

|Dec 26, 2025
Epidemiological evidence for the role of puberty and immune senescence in Hodgkin lymphoma aetiology from 1992 Danish cases.

Klaus Rostgaard, Stephen Hamilton-Dutoit, Kristina L Lauridsen

|Oct 20, 2025
Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial.

Martin Hutchings, Anna Sureda, Francesc Bosch

|Sep 08, 2025
Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma.

Lorenzo Falchi, Anna Sureda, Sirpa Leppä

Pageof 6

Frequent Collaborators

7 joint publications

Ingrid Glimelius

6 joint publications

Michael J Dickinson

4 joint publications

Anna Sureda

4 joint publications

Pieternella Lugtenburg